Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.30 |
| ▸ | MTOR | P42345 | 3/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14487501 | 0.88 | HTR2C (0.32) | — | |
| SCHEMBL14555680 | 0.84 | TLR8 (0.38) | — | |
| SCHEMBL17005360 | 0.83 | TLR8 (0.40) | — | |
| SCHEMBL12798680 | 0.81 | HTR2C (0.46) | — | |
| Hydrochloric Acid SCHEMBL16992579 | 0.80 | HTR2C (0.47) | — | |
| SCHEMBL17001833 | 0.78 | HTR1F (0.39) | MAP3K12KCNH2 | |
| SCHEMBL16475545 | 0.78 | RBP4 (0.31) | — | |
| SCHEMBL18965047 | 0.74 | PARP1 (0.39) | HTR1AKCNH2 | |
| SCHEMBL7906841 | 0.74 | TDP2 (0.33) | IRAK4DAO | |
| SCHEMBL1662947 | 0.73 | RBP4 (0.37) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | MAP3K12 3228/4885PTGS2 424/4885IDH1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.